A Uremic Toxin Absorbent (AST-120) to Treat Hospital Acquired Acute Kidney Injury
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Hospital acquired acute kidney injury is an important negative outcome predictor for
hospitalized patients. Uremic toxins accumulated after a given renal insult. Some of these
uremic toxins are protein bound and may accumulated after renal impairment, owing to both
impaired filtration, and inflammation. Recent animal studies have reported that accumulation
of uremic toxins, namely indoxyl sulfate and p-cresol, would down regulate endothelial
progenitor cells and in turn affect renal recovery. Elimination of these protein bound uremic
toxins with an activated charcoal would help restore endothelial function. We will conduct a
double blinded randomized placebo controlled trial, which aims to determine that if oral
activated charcoal will retard progression of AKI. Also, a panel of markers for endothelial
function will also be determined.
Phase:
Phase 3
Details
Lead Sponsor:
National Taiwan University Hospital
Collaborators:
Chang Gung Memorial Hospital China Medical University Hospital National Taiwan University Hospital Hsin-Chu Branch National Taiwan University Hospital, Yun-Lin Branch Taipei Medical University Hospital Taoyuan General Hospital